Company Description
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally.
The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs.
In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents.
OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Joshua Riggs |
Contact Details
Address: 15 Cushing Irvine, California 92618 United States | |
| Phone | 949 409 7600 |
| Website | oncocyte.com |
Stock Details
| Ticker Symbol | IMDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001642380 |
Key Executives
| Name | Position |
|---|---|
| Joshua Riggs | Chief Executive Officer |
| Andrea James | Chief Financial Officer |